Related Experiment Video
Updated: Oct 14, 2025

Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
Pediatric Mucormycosis and COVID-19
1Department of Dentistry, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh, India, Phone: +91 8872792010,
Abstract:
As of May 19, 2021, due to the increase in reported mucormycosis cases in COVID-19 patients, mucormycosis has been declared as a notifiable disease under Epidemic Disease Act 1897 by the Government of India with the prevalence being 140 per million population. The first case of mucormycosis in a pediatric COVID-19 positive child has been reported in Ahmedabad1 and we should prepare ourselves with the probability of more pediatric cases being reported in the near future.
Insights
Mucormycosis, a fungal infection, is now a notifiable disease in India due to rising COVID-19 cases. Pediatric cases are emerging, necessitating preparedness for future outbreaks.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Public Health
Background:
- Rising incidence of mucormycosis in COVID-19 patients prompted regulatory action.
- Mucormycosis is a serious fungal infection, often affecting immunocompromised individuals.
Observation:
- Mucormycosis declared a notifiable disease in India on May 19, 2021.
- Prevalence reported at 140 per million population.
- First pediatric COVID-19 associated mucormycosis case reported in Ahmedabad.
Findings:
- The declaration as a notifiable disease signifies a significant public health concern.
- The reported prevalence highlights the scale of the issue within the population.
Implications:
- Increased surveillance and reporting are expected for mucormycosis.
- Healthcare systems must prepare for a potential rise in pediatric mucormycosis cases.
- Further research into pediatric mucormycosis in COVID-19 patients is warranted.
Related Concept Videos
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Fungal Group Zygomycota
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pneumonia II: Pathophysiology
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...

